Jacob Linu Abraham, Asati Vikas, Lakshmaiah K C, Govind Babu K, Lokanatha Dasappa, Babu Suresh Mc, Lokesh K N, Rudresh A H, Rajeev L K, Mulchandani Nikita J, Anand Abhishek, Koppaka Deepak, Mysore Suma Narayana
Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.
Indian J Cancer. 2018 Apr-Jun;55(2):134-137. doi: 10.4103/ijc.IJC_418_17.
Skin is the second most common site for extranodal non-Hodgkin's lymphoma (NHL). Most primary cutaneous NHLs are of T-cell origin (70%). Primary cutaneous B-cell lymphoma (PCBCL) is a rare entity.
Patients diagnosed with PCBCL between January 2012 and July 2017 at our center were retrospectively analyzed.
Eight patients of PCBCL were diagnosed. Three patients (37.5%) were males while 5 patients (62.5%) were females. The median age at diagnosis was 45 years (range, 18-60 years). Scalp was the most common site of involvement (50% of the patients). Diffuse large B-cell lymphoma (DLBCL) was the most common histology (63%), with leg-type DLBCL diagnosed in 1 patient. Two patients had primary cutaneous follicle center lymphoma, whereas the remaining 1 patient had precursor B-lymphoblastic lymphoma. All 5 DLBCL cases were treated with CHOP chemotherapy, and rituximab was given to 3 patients. Of the primary cutaneous follicle center lymphomas, 1 patient with stage II disease was treated with CHOP and is alive without recurrence for the past 5 years, whereas the other patient is on observation alone. The patient with precursor B-lymphoblastic lymphoma was started on MCP-841 protocol; however, the patient did not complete the treatment and died after 11 months.
PCBCL is a heterogeneous group of diseases and dividing them into subtypes, based on morphology and immunophenotype, has therapeutic implications.
皮肤是结外非霍奇金淋巴瘤（NHL）的第二常见发病部位。大多数原发性皮肤NHL起源于T细胞（70%）。原发性皮肤B细胞淋巴瘤（PCBCL）是一种罕见的疾病。
对2012年1月至2017年7月在本中心诊断为PCBCL的患者进行回顾性分析。
共诊断出8例PCBCL患者。男性3例（37.5%），女性5例（62.5%）。诊断时的中位年龄为45岁（范围18 - 60岁）。头皮是最常受累的部位（50%的患者）。弥漫性大B细胞淋巴瘤（DLBCL）是最常见的组织学类型（63%），其中1例诊断为腿部型DLBCL。2例为原发性皮肤滤泡中心淋巴瘤，其余1例为前体B淋巴细胞母细胞淋巴瘤。所有5例DLBCL患者均接受CHOP化疗，3例患者加用利妥昔单抗。在原发性皮肤滤泡中心淋巴瘤患者中，1例II期患者接受CHOP治疗，过去5年无复发存活，而另1例患者仅接受观察。前体B淋巴细胞母细胞淋巴瘤患者开始接受MCP - 841方案治疗；然而，该患者未完成治疗，11个月后死亡。
PCBCL是一组异质性疾病，根据形态学和免疫表型将其分为亚型具有治疗意义。
